Yost KJ - Search Results

1

Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience.

Yost KJ, Eton DT. Yost KJ, et al. Eval Health Prof. 2005 Jun;28(2):172-91. doi: 10.1177/0163278705275340. Eval Health Prof. 2005. PMID: 15851772

2

Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches.

Yost KJ, Cella D, Chawla A, Holmgren E, Eton DT, Ayanian JZ, West DW. Yost KJ, et al. J Clin Epidemiol. 2005 Dec;58(12):1241-51. doi: 10.1016/j.jclinepi.2005.07.008. Epub 2005 Oct 13. J Clin Epidemiol. 2005. PMID: 16291468

3

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.

Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. Eton DT, et al. Among authors: yost kj. J Clin Epidemiol. 2004 Sep;57(9):898-910. doi: 10.1016/j.jclinepi.2004.01.012. J Clin Epidemiol. 2004. PMID: 15504633

4

Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy.

Eton DT, Yost KJ, Cella D. Eton DT, et al. Among authors: yost kj. Clin Lung Cancer. 2006 Sep;8(2):99-109. doi: 10.3816/CLC.2006.n.037. Clin Lung Cancer. 2006. PMID: 17026810 Review.

5

Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI).

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Yost KJ, et al. Breast Cancer Res Treat. 2005 Apr;90(3):295-8. doi: 10.1007/s10549-004-5024-3. Breast Cancer Res Treat. 2005. PMID: 15830143

6

Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients.

Yost KJ, Eton DT, Garcia SF, Cella D. Yost KJ, et al. J Clin Epidemiol. 2011 May;64(5):507-16. doi: 10.1016/j.jclinepi.2010.11.018. J Clin Epidemiol. 2011. PMID: 21447427 Free PMC article.

7

Effects of patient-reported outcome assessment order.

Novotny PJ, Dueck AC, Satele D, Frost MH, Beebe TJ, Yost KJ, Lee MK, Eton DT, Yount S, Cella D, Mendoza TR, Cleeland CS, Blinder V, Basch E, Sloan JA. Novotny PJ, et al. Among authors: yost kj. Clin Trials. 2022 Jun;19(3):307-315. doi: 10.1177/17407745211073788. Epub 2022 Jan 28. Clin Trials. 2022. PMID: 35088616 Free PMC article. Clinical Trial.

8

The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma.

Yost KJ, Thompson CA, Eton DT, Allmer C, Ehlers SL, Habermann TM, Shanafelt TD, Maurer MJ, Slager SL, Link BK, Cerhan JR. Yost KJ, et al. Leuk Lymphoma. 2013 Feb;54(2):290-7. doi: 10.3109/10428194.2012.711830. Epub 2012 Sep 6. Leuk Lymphoma. 2013. PMID: 22799432 Free PMC article.

9

Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden.

Eton DT, Yost KJ, Lai JS, Ridgeway JL, Egginton JS, Rosedahl JK, Linzer M, Boehm DH, Thakur A, Poplau S, Odell L, Montori VM, May CR, Anderson RT. Eton DT, et al. Among authors: yost kj. Qual Life Res. 2017 Feb;26(2):489-503. doi: 10.1007/s11136-016-1397-0. Epub 2016 Aug 26. Qual Life Res. 2017. PMID: 27566732 Free PMC article.

10

General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G).

Brucker PS, Yost K, Cashy J, Webster K, Cella D. Brucker PS, et al. Eval Health Prof. 2005 Jun;28(2):192-211. doi: 10.1177/0163278705275341. Eval Health Prof. 2005. PMID: 15851773

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters